Positive recommendation based on phase II NOBILITY and phase III REGENCY data showing Gazyva/Gazyvaro’s superiority over standard therapy alone1,2Gazyva/Gazyvaro is the only anti-CD20 antibody to ...
54m
F. Hoffmann-La Roche Ltd: CHMP recommends EU approval of Roche's Gazyva/Gazyvaro for lupus nephritis
Positive recommendation based on phase II NOBILITY and phase III REGENCY data showing Gazyva/Gazyvaro's superiority over standard therapy alone1,2 Gazyva/Gazyvaro is the only anti-CD20 antibody to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback